Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer
نویسندگان
چکیده
منابع مشابه
Exemestane in early breast cancer: a review
The adjuvant treatment of women with endocrine-sensitive early breast cancer has been dominated for the last 40 years by tamoxifen. However, the side-effects associated with this therapy have prompted a search for safer and biochemically more selective endocrine agents and led to the development of the third-generation aromatase inhibitors (AIs) anastrozole, letrozole and exemestane. Promising ...
متن کاملAn ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
BACKGROUND Breast cancer patients with positive estrogen receptor (ER) have a better prognosis. However, no prognostic miRNA signature was reported in the ER-positive breast cancer. The aim of the study was to identify and assess the prognostic significance of a miRNA signature in ER-positive breast cancer. METHODS Two cohorts from The Cancer Genome Atlas (TCGA) dataset were used as training ...
متن کاملExemestane: a milestone against breast cancer.
Rapid advances in the treatment of breast cancer, especially in the form of hormone therapy have truly increased the hope of longer and better disease-free survival for these patients. Exemestane, a third generation aromatase inhibitor has been extensively evaluated in metastatic as well as adjuvant therapy of breast cancer. It has also been evaluated for its safety profile, especially on bone ...
متن کاملCost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
INTRODUCTION Exemestane was approved in 2005 for adjuvant treatment of breast cancer. In this study, we aimed to assess whether it is cost-effective in comparison to available alternatives. MATERIAL AND METHODS To evaluate the efficacy of exemestane, a systematic review was conducted by searching electronic databases. The outcomes of interest were "clinical benefit", "overall response" and "d...
متن کاملAGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
Endocrine resistance is a significant problem in breast cancer treatment. Thus identification and validation of novel resistance determinants is important to improve treatment efficacy and patient outcome. In our work, AGR2 expression was determined by qRT-PCR in Tru-Cut needle biopsies from tamoxifen-treated postmenopausal breast cancer patients. Our results showed inversed association of AGR2...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Technology in Cancer Research & Treatment
سال: 2020
ISSN: 1533-0346,1533-0338
DOI: 10.1177/1533033819896331